Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to increase access to medication for people with IBD.

The National Institute for Health and Care Excellence (NICE) is the independent body that makes recommendations on whether all new medicines and significant licence extensions for existing medicines should be routinely funded by the National Health Service in England based on an assessment of clinical and cost effectiveness. In the last three years, NICE has recommended five new drugs for the treatment of moderate to severe Crohn’s disease and ulcerative colitis, including upadacitinib, risankizumab, mirikizumab, etrasimod, and guselkumab. The NHS in England is legally required to fund medicines recommended by NICE, normally within three months of the publication of final guidance.